友邦預留1億元作免費疫苗副作用保障
友邦香港公布,為鼓勵市民積極接種疫苗提供獎賞,「AIA Vitality 健康程式」會員接種流感疫苗、乙型肝炎疫苗、甲型及乙型肝炎疫苗、HPV疫苗(女性 18-26歲),以及最新加入的「2019冠狀病毒病」疫苗,可賺取1,000積分。若客戶已接種「2019冠狀病毒病」疫苗並成功投保AIA「智遊保」可享有合共200元保費折扣優惠。
公司並預留合共1億港元或澳門幣「免費疫苗副作用防護保障」,包括住院前門診賠償、住院現金賠償及不幸離世的恩恤金,客戶無須登記便可自動享有保障,涵蓋範圍包括季節性流感疫苗、乙型肝炎疫苗及「2019冠狀病毒病」疫苗等在香港及澳門處方及注射認可的疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.